Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting. (PubMed, Cell Biol Int) - Oct 4, 2026 - "Targeted strategies, including IDH1/2 inhibitors (ivosidenib and enasidenib), BCL-2 inhibition (venetoclax), niche-disrupting agents (plerixafor and uproleselan), OXPHOS inhibitors (IACS-010759 and metformin), and immunometabolic interventions such as IDO1 inhibitors and CAR-T therapies represent emerging precision approaches. Collectively, this integrative framework highlights the BM microenvironment as a central regulator of cancer cell metabolism and immune evasion, underscoring the potential of immunometabolic targeting to overcome therapeutic resistance and enable next-generation precision medicine in hematologic diseases."
Journal • Review • Acute Myelogenous Leukemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • CXCL12 • HIF1A • IDH1 • IDH2
|
|
Adrian Khu; Alexander P Marpaung; Alexander Patera Nugraha; Amama Rani; Bonglee Kim; Fahrul Nurkolis; Princella Halim; Putri Cahaya Situmorang; Rony Abdi Syahputra; Rosy Iara Maciel de Azambuja Ribeiro
|